Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Alexandra Zatarain,
Eight Sleep
Getting to Product-Market Fit [Entire Talk]
Product-market fit is a journey. Knowing your audience and mission will help you on your way.
Alexandra Zatarain,
Eight Sleep
Getting to Product-Market Fit [Entire Talk]
Product-market fit is a journey. Knowing your audience and mission will help you on your way.
Maria Barrera,
Clayful
Mental Health Tech, Mentally Healthy Startups [Entire Talk]
Startups can address important mental health problems, but maintaining mental health in startup culture is challenging.
Maria Barrera,
Clayful
Mental Health Tech, Mentally Healthy Startups [Entire Talk]
Startups can address important mental health problems, but maintaining mental health in startup culture is challenging.
David Allemann,
On
Exploration in Sports Technology [Entire Talk]
Taking a risk on an innovative idea can be the spark of a global company.
David Allemann,
On
Exploration in Sports Technology [Entire Talk]
Taking a risk on an innovative idea can be the spark of a global company.
